Cargando…

Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease

BACKGROUND: There is limited information available regarding the clinical management of intravenous immunoglobulin-resistant Kawasaki disease (KD). We aimed to evaluate the optimal treatment options for patients with refractory KD by presenting an indirect-comparison meta-analysis. METHODS: PubMed,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Han, Chi, Huan, You, Hui, Wang, Mo, Zhang, Gaofu, Yang, Haiping, Li, Qiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524334/ https://www.ncbi.nlm.nih.gov/pubmed/31101091 http://dx.doi.org/10.1186/s12887-019-1504-9

Ejemplares similares

Infliximab Treatment for Refractory Kawasaki Disease in Korean Children
por: Song, Min Seob, et al.
Publicado: (2010)

Risk factors associated with IgA vasculitis with nephritis (Henoch–Schönlein purpura nephritis) progressing to unfavorable outcomes: A meta-analysis
por: Shi, Dongmei, et al.
Publicado: (2019)

Recurrent refractory Kawasaki disease
por: Costa Reis, P, et al.
Publicado: (2011)

Predicting Factors for Refractory Kawasaki Disease
por: Do, Young-Sun, et al.
Publicado: (2010)

Infliximab as rescue therapy in refractory Kawasaki disease
por: Rodríguez-González, Moisés, et al.
Publicado: (2014)

Refractory Kawasaki disease: diagnostic and management challenges
por: Duignan, Sophie, et al.
Publicado: (2019)

Cyclosporine for refractory Kawasaki disease with psoriasiform eruption
por: Leyendecker, Mara, et al.
Publicado: (2021)

Refractory Kawasaki Disease—a Challenge for the Pediatrician
por: Abraham, Deepu, et al.
Publicado: (2021)

Clinical outcome of patients with refractory Kawasaki disease based on treatment modalities
por: Kim, Hyun Jung, et al.
Publicado: (2016)

Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms
por: Halyabar, Olha, et al.
Publicado: (2021)

γδT Cells Exacerbate Podocyte Injury via the CD28/B7-1-Phosphor-SRC Kinase Pathway
por: Chen, Wanbing, et al.
Publicado: (2018)

Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review
por: Crayne, Courtney B., et al.
Publicado: (2019)

Comparison of Clinical Features and Inflammatory Markers between Kawasaki Disease Shock Syndrome and Kawasaki Disease without Shock: A Meta-Analysis
por: Zhang, Hui, et al.
Publicado: (2021)

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
por: Cancanelli, Luca, et al.
Publicado: (2023)

CD36 Promotes Podocyte Apoptosis by Activating the Pyrin Domain-Containing-3 (NLRP3) Inflammasome in Primary Nephrotic Syndrome
por: Yang, Xuejun, et al.
Publicado: (2018)

Treatment Options in Refractory Autoimmune Encephalitis
por: Dinoto, Alessandro, et al.
Publicado: (2022)

Bartter Syndrome Type 3: Phenotype-Genotype Correlation and Favorable Response to Ibuprofen
por: Yang, Xuejun, et al.
Publicado: (2018)

Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment
por: Seo, Euri, et al.
Publicado: (2016)

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Proskorovsky, Irina, et al.
Publicado: (2019)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

Multiple treatment and indirect treatment comparisons: An overview of network meta-analysis
por: Bhatnagar, Nidhi, et al.
Publicado: (2014)

Severe refractory Kawasaki disease in seven infants in the COVID-19 era
por: Vergnano, Stefania, et al.
Publicado: (2020)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease
por: Samadli, Sama, et al.
Publicado: (2019)

A novel FOXP3 mutation in a Chinese child with IPEX‐associated membranous nephropathy
por: Tan, Liwen, et al.
Publicado: (2022)

Selecting treatment options in refractory metastatic colorectal cancer
por: Byrne, Margaret, et al.
Publicado: (2019)

New Treatment Options for Refractory/Resistant CMV Infection
por: Walti, Carla Simone, et al.
Publicado: (2023)

Risk factors for refractory Kawasaki disease: clinical records of the paediatric clinic of palermo
por: Maggio, Maria Cristina, et al.
Publicado: (2014)

Infliximab as a rescue therapy in the management of refractory typical infantile Kawasaki disease
por: Venkatnarayanan, K., et al.
Publicado: (2020)

Metastatic renal cell cancer treatments: An indirect comparison meta-analysis
por: Mills, Edward J, et al.
Publicado: (2009)

Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
por: Luo, Xian-Wu, et al.
Publicado: (2018)

Retracted: Comparison of Clinical Features and Inflammatory Markers between Kawasaki Disease Shock Syndrome and Kawasaki Disease without Shock: A Meta-Analysis
por: Healthcare Engineering, Journal of
Publicado: (2023)

Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis
por: Qin, Di, et al.
Publicado: (2022)

Acupuncture vs. antispasmodics in the treatment of irritable bowel syndrome: An adjusted indirect treatment comparison meta-analysis
por: Shi, Yun-zhou, et al.
Publicado: (2022)

Novel SARS2 variants identified in a Chinese girl with HUPRA syndrome
por: Zhou, Yi, et al.
Publicado: (2021)

Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives
por: Buda, Piotr, et al.
Publicado: (2021)

Atopic dermatitis: Tofacitinib, an option for refractory disease
por: Berbert Ferreira, Sineida, et al.
Publicado: (2020)

Kawasaki Disease Shock Syndrome vs Classical Kawasaki Disease: A Meta-analysis and Comparison With SARS-CoV-2 Multisystem Inflammatory Syndrome
por: Lamrani, Loubna, et al.
Publicado: (2021)

Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis
por: Qiu, Shiyuan, et al.
Publicado: (2021)

Comparison between Kawasaki disease with lymph-node-first presentation and Kawasaki disease without cervical lymphadenopathy
por: Kim, Jung Ok, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g0jrk1vb97re602p7sc83aonrn